Source: Annual Congress 2012 - Diffuse parenchymal lung disease pathogenesis, biomarkers, therapy and new entities
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Gómez-Seco, M.J. Rodríguez-Nieto, F. Romero-Bueno, S. Recuero-Díaz, T. Presa-Abos, O. Sánchez-Pernaute, F. Villar-Álvarez, I. Fernández-Ormaechea (Madrid, Spain). Efficacy of rituximab in patients with connective tissue disease associated interstitial lung disease: Preliminary results in safety and clinical response. Eur Respir J 2012; 40: Suppl. 56, 1779

Member's Comments

No comment yet.

Related content which might interest you: An observational study on effectiveness of azathioprine in treatment of interstitial lung disease secondary to connective tissue disease Source: International Congress 2019 – Assessment and management of immune-mediated interstitial lung diseases Year: 2019 The efficacy of pirfenidone in scleroderma related interstitial lung disease Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012 Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials Source: International Congress 2016 – IPF treatment I Year: 2016 Efficacy of switching from cyclosporine A to tacrolimus in patients with refractory CTD-ILD Source: International Congress 2016 – Connective tissue disorders Year: 2016 Frequency and impact of interstitial lung disease on clinical state and mortality in systemic scleroderma Source: Annual Congress 2012 - Diffuse parenchymal lung disease III Year: 2012 Safety and tolerability of pirfenidone (PFD) in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD)–The LOTUSS study Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases Year: 2015 Safety and tolerability of nintedanib in patients with fibrosing interstitial lung diseases: pooled data from four trials Source: Virtual Congress 2021 – Interstitial lung disease, COVID-19 and friends Year: 2021 A multicentre evaluation of inter-multidisciplinary team agreement for predicted disease behaviour and management strategy in diffuse lung disease Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases Year: 2016 Clinical characteristics of 30 patients with interstitial pneumonia associated with anti-aminoacyl-tRNA-synthetase antibodies Source: International Congress 2016 – Connective tissue disorders Year: 2016 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Physical activity and clinical outcomes in patients with interstitial lung disease: how large is the impairment? – Preliminary results Source: International Congress 2018 – Chronic respiratory disease : determinants of physical activity in patients Year: 2018 Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy}, Source: Eur Respir J 2012; 40: 641-648 Year: 2012 Predictors of mortality and risk prediction among patients with scleroderma related interstitial lung disease Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 Intravenous cyclophosphamide therapy for patients with interstitial pulmonary disease associated with collagen vascular disorders. A single-center experience Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders Year: 2008 Hemodynamics and response to therapy of pulmonary hypertension in patients with interstitial lung disease: Preliminary results of the "HYPID" prospective study Source: Annual Congress 2012 - Pulmonary circulation: clinical treatment Year: 2012 Predictors of progression in systemic sclerosis patients with interstitial lung disease Source: Eur Respir J, 55 (5) 1902026; 10.1183/13993003.02026-2019 Year: 2020 Interstitial lung disease Source: Eur Respir Rev 2013; 22: 26-32 Year: 2013 Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry Source: Eur Respir J, 56 (2) 1902279; 10.1183/13993003.02279-2019 Year: 2020 Efficacy of pulmonary rehabilitation in patients with interstitial lung disease Source: Annual Congress 2012 - The best posters in pulmonary rehabilitation and chronic care Year: 2012 A multicentre evaluation of inter-multidisciplinary team agreement for diagnosis in diffuse lung disease Source: International Congress 2016 – Epidemiological and clinical data regarding the modern management of chronic lung diseases Year: 2016